The risk and cost-effective individual patient management: The challenge of a new generation of clinical trials

Cardiovascular Drugs and Therapy

Volumn 10, Issue 6, 1997, Pages 751-758

  Maseri, Attilio ^a,b   Cianflone, Domenico ^a   Pasceri, Vincenzo ^a   Crea, Filippo ^a  

^a CATHOLIC UNIVERSITY   (Italy)

^b FONDAZIONE POLICLINICO UNIVERSITARIO A GEMELLI IRCCS   (Italy)

Author keywords

Health care economics; Individual stratification of absolute risk; Life expectancy; Quality of life

Indexed keywords

ACETYLSALICYLIC ACID; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FIBRINOLYTIC AGENT; NITRATE; STATIN; STREPTOKINASE; TISSUE PLASMINOGEN ACTIVATOR;

ACUTE HEART INFARCTION; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DRUG COST; HEALTH ECONOMICS; HUMAN; ISCHEMIC HEART DISEASE; LIFE EXPECTANCY; MORTALITY; PATIENT CARE; PATIENT COMPLIANCE; PHYSICIAN; PRIORITY JOURNAL; PROGNOSIS; QUALITY OF LIFE; REVIEW; RISK MANAGEMENT; STATISTICAL ANALYSIS; UNSTABLE ANGINA PECTORIS;

EID: 0030965448     PISSN: 09203206     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF00053033     Document Type: Review

References (30)

1. Maseri A. Ischemic Heart Disease. New York:Churchill Livingstone, 1995:377-405.
2. Lau J, Antman EM, Jimenez-Silva J, Kupelnick B, Mosteller F, Chalmers TC. Cumulative meta-analysis of therapeutic trials for myocardial infarction. N Engl J Med 1992; 327:248.
3. Thomas L. The Lives of a Cell: Your Very Good Health. New York: Viking Press, 1974.
4. Hampton JR. The end of clinical freedom. Br Med J 1983; 287:1237-1238.
5. Maseri A. Medical therapy of chronic stable angina pectoris. Circulation 1990;82:2258-2262.
6. The Cardiac Arrhythmia Suppression Trial (CAST) Investigators. Preliminary report. Effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. N Engl J Med 1989; 321:406.
7. Horton R. Spinning the risks and benefits of calcium antagonists. Lancet 1995;346:586-587.
8. Smith GD, Song F, Sheldon TA. Cholesterol lowering and mortality: The importance of considering the initial level of risk. Br Med J 1993;306:1367.
9. U.S. Department of Health and Human Services. Public Health Service. Agency for Health Care Policy and Research National Heart, Lung, and Blood Institute. Unstable angina: Diagnosis and management. Clinical Practice Guideline, 10, 1994.
10. Gruppo Italiano per lo Studio della Sopravvivenza nell'infarto Miocardico. GISSI-3. Effects of lisinopril and transdermal nitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction. Lancet 1994;343:1115-1122.
11. ISIS-4 (Fourth International Study on Infarct Survival) Collaborative group. ISIS-4: A randomised factorial trial assessing early oral captopril, oral mononitrate and intravenous magnesium in 58,000 patients with suspected acute myocardial infarction. Lancet 1995;345:669-685.
12. AIRE (Acute Infarction Ramipril Efficacy) Investigators. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet 1993;342:821-828.
13. Yusuf S, Collins R, MacMahon S, Peto R. Effect of intravenous nitrates on mortality in acute myocardial infarction: An overview of randomised trials. Lancet 1988; 1:1088-1092.
14. Fibrinolytic Therapy Trialists (FTT) Collaborative Group. Indications for fibrinolytic therapy in suspected acute myocardial infarction: Collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients. Lancet 1994;343:311-322.
15. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-1389.
16. Shepherd J, Cobbe SM, Ford I, et al. for the West of Scotland Coronary Prevention Study Group. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995;333:1301-1307.
17. Brown MS, Goldstein JL. Heart attacks: Gone with the century? Science 1996;272:629.
18. Anderson KM, Castelli WP, Levy D. Cholesterol and mortality. 30 years of follow-up from the Framingham Study. JAMA 1987;257:2176.
19. Thompson SG, Kienast J, Pyke S, Haverkate F, van de Loo JPW for the European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. N Engl J Med 1995;332: 635-641.
20. Gruppo Italiano per lo Studio della Streptochinasi nell'Infarto Miocardico (GISSI). Long-term effects of intravenous thrombolysis in acute myocardial infarction: Final report of the GISSI Study. Lancet 1987;2:871.
21. Sweeney MO, Ruskin JN, Garan H, et al. Influence of the implantable cardioverter/defibrillator on sudden death and total mortality in patients evaluated for cardiac transplantation. Circulation 1995;92:3273-3281.
22. Tsevat J, Weinstein MC, Williams LW, Tosteson ANA, Goldman L. Expected gains in life expectancy from various coronary heart disease risk factor modifications. Circulation 1991;83:1194-1201.
23. Curtin LR, Armstrong RJ (NCHS). United States life tables eliminating certain causes of death. U.S. Decennal Life Tables for 1979-82. Department of Health and Human Services publication no. (PHS) 1988;88:1150.
24. Maseri A. Ischemic Heart Disease. New York: Churchill Livingstone, 1995:685-691.
25. The GUSTO Investigators. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med 1993;329:673.
26. The GUSTO Angiographic Investigators. The effects of plasminogen activator, streptokinase, or both on coronary-artery patency, ventricular function, and survival after acute myocardial infarction. N Engl J Med 1993;329:1615.
27. Maseri A. An unresolved, persisting challenge for percutaneous transluminal coronary angioplasty: How to identify the lesions that will not restenose. Eur Heart J 1996;17: 814-815.
28. G7 Cardio Project. Risk stratification of patients with cardiovascular disease. Proceedings of the Rome meeting 1996.
29. Feinstein AR. Clinical judgement revisited: The distraction of quantitative models. Ann Int Med 1994;120:799.
30. Kassirer JP. Incorporating patients' preferences into medical decisions. N Engl J Med 1994;330:1895-1896.